BioSpace News Archive

Lipocine Inc. announces positive topline results from its Open Label Extension study, OLE. LPCN 1144 comprises an orally delivered prodrug of testosterone.

On World Fibromyalgia Awareness Day ( May 12 ), the French startup Remedee Labs is announcing that the FDA has granted Breakthrough Device Designation to its endorphin stimulator for fibromyalgia patients.

Wysa, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its AI-based digital mental health conversational agent for patients 18 years and older with a diagnosis of chronic musculoskeletal pain (defined as pain lasting longer than three months) and depression and anxiety.

AmerisourceBergen Corporation (NYSE: ABC) today announced that it is resuming share repurchases with excess free cash flow in accordance with the company’s disciplined approach to capital allocation.

Unlearn®, developer of the first machine-learning technology that creates digital twins of patients in clinical trials to enable smaller, faster studies, today announced that the European Medicines Agency (EMA) recently released a draft qualification opinion providing a regulatory framework for the application of the company’s TwinRCT™ solution to Phase 2 and 3 clinical trials.

Equillium, Inc. announced that the European Hematology Association has published an abstract highlighting the Phase 3 EQUATOR study in first-line acute graft-versus-host disease.

Alto Neuroscience today announced that founder and chief executive officer, Amit Etkin, M.D., Ph.D., has been appointed to serve as a member of the National Institute on Drug Abuse’s (NIDA) National Advisory Council on Drug Abuse (NACDA).

The PPD clinical research business of Thermo Fisher Scientific, the world leader in serving science, has been distinguished for industry leadership in digital and decentralized clinical trial solutions by Information Services Group (ISG), a leading global technology research and advisory firm.

Longboard Pharmaceuticals, Inc. announced that members of its senior leadership team will participate in the Citi Movement Disorder & Epilepsy Co-Panel, on May 18, 2022, and present virtually in a fireside chat format at the H.C. Wainwright Global Investment Hybrid Conference, which is taking place May 23-26, 2022.

Collinson, a global leader in the provision of medical assistance and Aspen Medical, a global provider of innovative healthcare solutions, have entered into joint venture to provide a new offering of best-in-class medical support.